Ken Griffin
MSLE

Ken Griffin’s Satellos Bioscience MSLE Stock Holding History

Ken Griffin’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239K Buy
+42,492
New +$417K ﹤0.01% 11016

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ken Griffin's MSLE Position: Q1 2026 in Review

Ken Griffin opened a new position in Satellos Bioscience (MSLE) in Q1 2026: 42,492 shares worth $239K. The stake represents ﹤0.01% of the portfolio and ranks #11016 among its holdings.

31 funds tracked by Wall St. Rank hold MSLE as of Q1 2026.

  • Ken Griffin held 42,492 shares of Satellos Bioscience worth $239K as of Q1 2026.
  • Satellos Bioscience was a new Ken Griffin position in Q1 2026.
  • Satellos Bioscience made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #11016 holding.
  • 31 funds tracked by Wall St. Rank held Satellos Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.